CClinicalTrials.gg
RecruitingNCT07023887EXERT-BCHCUpdated Sep 30, 2026

Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning

An observational study in Cancer and Breast Cancer, sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute). Recruiting at 1 site in United States. Open to female participants aged 20 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15
Ages
20 Years to 89 Years
Sex
Female
01

Study summary

This study investigates the impact of four standard of care, monitored group exercise regimens (resistance training) on conditioning and hypertrophy in women previously treated for breast cancer. The study will compare two conditioning regimens (6-12-25 and 8x8) and two hypertrophy regimens (5/5/5 cluster sets and double training) to assess changes in VO2 max, muscle mass, and fat mass.

02

Conditions studied

  • Cancer
  • Breast Cancer

Keywords

  • exercise
03

Who can participate

Ages eligible
20 Years to 89 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be recruited via convenience sampling from the Study Investigators' practice patient population, referrals from other physicians' practices, or identifiable medical record review (e.g., EPIC).

Inclusion criteria

  1. Age 20-89 years
  2. Women prescribed exercise as a Standard of Care
  3. Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast
  4. Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy.
  5. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed.
  6. Women with > 6 months of resistance training experience under expert guidance by a CSCS

Exclusion criteria

Exclusion Criteria:

  1. Any current treatment with cytotoxic chemotherapy for breast cancer
  2. Inability to safely engage in group sessions of resistance training as deemed by study Pl
  3. Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by Pl to be unsafe to engage in resistance training
  4. Beta blocker or GLP-1 inhibitor medications
  5. Pregnant women
  6. Males
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15 participants (estimated)
Patient registry
No

Interventions

  • Other6-12-25 Training Regimen

    A conditioning regimen involving three exercises performed consecutively with minimal rest. Includes 4-6 repetitions at 4-0-1-0 tempo, 10-12 repetitions at 3-0-1-0 tempo, and 20-25 repetitions at 2-0-1-0 tempo.

  • Other8x8 Training Regimen

    A conditioning regimen optimizing high volume with short rest periods. Six exercises are performed consecutively with a 2-0-1-0 tempo and no rest between sets.

  • Other5/5/5 Cluster Set Training Regimen

    A hypertrophy regimen where an individual performs 5 repetitions at a tempo of 4 seconds during the eccentric movement of the exercise, while performing the concentric motion in 1 second then resting for 20 seconds and repeating the sequence two additional times to total three clusters of 5 repetitions.

  • OtherDouble Training Regimen

    A hypertrophy regimen adding an additional set of lesser repetitions for a specified exercise at the end of a tri-set of exercises.

05

What researchers measure

Primary outcomes

  1. Change in VO2 max

    Change in maximal oxygen consumption (VO2 max) measured during and after each exercise regimen.

    Time frame: Measured monthly during the 5-month exercise program at weeks 4, 8, 12, 16, and 20.

  2. Change in Muscle and Fat Mass

    Change in muscle mass and fat mass in pounds as measured by InBody 970.

    Time frame: Baseline, at the completion of the 5-month exercise program (Week 20), and monthly during the exercise program at weeks 4, 8, 12, and 16.

  3. Change in Muscle and Fat Mass

    Change in muscle mass and fat mass in pounds as measured by ultrasound.

    Time frame: Baseline, at the completion of the 5-month exercise program (Week 20), and monthly during the exercise program at weeks 4, 8, 12, and 16.

Secondary outcomes

  1. Change in Hand Grip Strength

    Measurement of hand grip strength using a dynamometer to assess upper body strength and function.

    Time frame: Baseline, at the completion of the 5-month exercise program (Week 20), and monthly during the exercise program at weeks 4, 8, 12, and 16.

  2. Change in Psychology Questionnaire Scores

    Assessment of psychological well-being, including confidence, motivation (intrinsic \& extrinsic), anxiety, and depression, using a Psychological Screen for Strength Training questionnaire. The responses to the variables will be calculated. The rating scale will be calculated 0-3. Not at all (0), some of the time (1), most of the time (2), and all the time (3).

    Time frame: Baseline, at the completion of the 5-month exercise program (Week 20), and monthly during the exercise program at weeks 4, 8, 12, and 16.

06

Study locations

1 of 1 sites recruiting
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
    • Clinical Trials Contact · Contact · ctgov@ahn.org · 4123306151
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided — Upon reasonable request the investigators plan to share unidentified data

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07023887
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Responsible party
Colin Champ, MD (Principal Investigator, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)) — Principal investigator
First posted
Jun 17, 2025
Start date
May 21, 2025
Primary completion
May 3, 2027 (estimated)
Completion
May 3, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Clinical Trials Contact
Contact
ctgov@ahn.org
412-330-6151
Colin Champ
principal investigator · AHN Radiation Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion